{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:33:15Z","timestamp":1792787595185,"version":"4.5.0"},"reference-count":33,"publisher":"American Association for Cancer Research (AACR)","issue":"5","funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["4P01 CA163222-04"],"award-info":[{"award-number":["4P01 CA163222-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"UT | University of Texas MD Anderson Cancer Center (MD Anderson)","doi-asserted-by":"publisher","award":["Melanoma Moon Shots"],"award-info":[{"award-number":["Melanoma Moon Shots"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["4P01 CA163222-04"],"award-info":[{"award-number":["4P01 CA163222-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Texas Rising STARS"},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance (MRA)","doi-asserted-by":"publisher","award":["508743"],"award-info":[{"award-number":["508743"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["R01CA203964"],"award-info":[{"award-number":["R01CA203964"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["R01CA203964"],"award-info":[{"award-number":["R01CA203964"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["R01CA182635"],"award-info":[{"award-number":["R01CA182635"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sheldon and Miriam Adelson Medical Research Foundation"},{"DOI":"10.13039\/100007313","name":"UT | University of Texas MD Anderson Cancer Center (MD Anderson)","doi-asserted-by":"publisher","award":["Melanoma Moon Shots"],"award-info":[{"award-number":["Melanoma Moon Shots"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Combined MEK and CDK4\/6 inhibition (MEKi + CDK4i) has shown promising clinical outcomes in patients with NRAS-mutant melanoma. Here, we interrogated longitudinal biopsies from a patient who initially responded to MEKi + CDK4i therapy but subsequently developed resistance. Whole-exome sequencing and functional validation identified an acquired PIK3CAE545K mutation as conferring drug resistance. We demonstrate that PIK3CAE545K preexisted in a rare subpopulation that was missed by both clinical and research testing, but was revealed upon multiregion sampling due to PIK3CAE545K being nonuniformly distributed. This resistant population rapidly expanded after the initiation of MEKi + CDK4i therapy and persisted in all successive samples even after immune checkpoint therapy and distant metastasis. Functional studies identified activated S6K1 as both a key marker and specific therapeutic vulnerability downstream of PIK3CAE545K-induced resistance. These results demonstrate that difficult-to-detect preexisting resistance mutations may exist more often than previously appreciated and also posit S6K1 as a common downstream therapeutic nexus for the MAPK, CDK4\/6, and PI3K pathways.<\/jats:p>\n                  <jats:p>Significance: We report the first characterization of clinical acquired resistance to MEKi + CDK4i, identifying a rare preexisting PIK3CAE545K subpopulation that expands upon therapy and exhibits drug resistance. We suggest that single-region pretreatment biopsy is insufficient to detect rare, spatially segregated drug-resistant subclones. Inhibition of S6K1 is able to resensitize PIK3CAE545K-expressing NRAS-mutant melanoma cells to MEKi + CDK4i. Cancer Discov; 8(5); 556\u201367. \u00a92018 AACR.<\/jats:p>\n                  <jats:p>See related commentary by Sullivan, p. 532.<\/jats:p>\n                  <jats:p>See related article by Teh et al., p. 568.<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 517<\/jats:p>","DOI":"10.1158\/2159-8290.cd-17-0745","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T20:35:28Z","timestamp":1519936528000},"page":"556-567","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["A Preexisting Rare\n                    <i>PIK3CA<\/i>\n                    E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4\/6 Inhibition in\n                    <i>NRAS<\/i>\n                    Melanoma and Is Dependent on S6K1 Signaling"],"prefix":"10.1158","volume":"8","author":[{"given":"Gabriele","family":"Romano","sequence":"first","affiliation":[{"name":"1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Ling","family":"Chen","sequence":"additional","affiliation":[{"name":"2Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"3Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Song","sequence":"additional","affiliation":[{"name":"4Department of Bioengineering, Rice University, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"McQuade","sequence":"additional","affiliation":[{"name":"5Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Liang","sequence":"additional","affiliation":[{"name":"1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingguang","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whijae","family":"Roh","sequence":"additional","affiliation":[{"name":"2Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dzifa Y.","family":"Duose","sequence":"additional","affiliation":[{"name":"1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.L.","family":"Carapeto","sequence":"additional","affiliation":[{"name":"1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"2Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.F.","family":"Teh","sequence":"additional","affiliation":[{"name":"6Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Aplin","sequence":"additional","affiliation":[{"name":"6Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania."},{"name":"7Department of Cutaneous Biology and Dermatology, Thomas Jefferson University, Philadelphia, Pennsylvania."},{"name":"8Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merry","family":"Chen","sequence":"additional","affiliation":[{"name":"9Department of Neurooncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Lazar","sequence":"additional","affiliation":[{"name":"1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[{"name":"1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"5Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Andrew","family":"Futreal","sequence":"additional","affiliation":[{"name":"2Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodabe N.","family":"Amaria","sequence":"additional","affiliation":[{"name":"5Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y.","family":"Zhang","sequence":"additional","affiliation":[{"name":"4Department of Bioengineering, Rice University, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Wargo","sequence":"additional","affiliation":[{"name":"2Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"9Department of Neurooncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence N.","family":"Kwong","sequence":"additional","affiliation":[{"name":"1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2018,4,30]]},"reference":[{"key":"2022060701170286800_bib1","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"2022060701170286800_bib2","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"2022060701170286800_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022060701170286800_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"2022060701170286800_bib5","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1073\/pnas.1216013110","article-title":"Combined targeting of MEK and PI3K\/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo","volume":"110","author":"Posch","year":"2013","journal-title":"PNAS"},{"key":"2022060701170286800_bib6","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/nm.2941","article-title":"Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma","volume":"18","author":"Kwong","year":"2012","journal-title":"Nat Med"},{"key":"2022060701170286800_bib7","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat Med"},{"key":"2022060701170286800_bib8","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-15-3384","article-title":"An in vivo reporter to quantitatively and temporally analyze the effects of CDK4\/6 inhibitor-based therapies in melanoma","author":"Teh","year":"2016","journal-title":"Cancer Res"},{"key":"2022060701170286800_bib9","doi-asserted-by":"crossref","first-page":"9009","DOI":"10.1200\/jco.2014.32.15_suppl.9009","article-title":"A phase 1b\/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activity","volume":"32","author":"Sosman","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022060701170286800_bib10","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"2022060701170286800_bib11","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1073\/pnas.0510857103","article-title":"Cancer-specific mutations in PIK3CA are oncogenic in vivo","volume":"103","author":"Bader","year":"2006","journal-title":"PNAS"},{"key":"2022060701170286800_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12967-015-0401-8","article-title":"Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas","volume":"13","author":"Manca","year":"2015","journal-title":"J Transl Med"},{"key":"2022060701170286800_bib13","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas","year":"2015","journal-title":"Cell"},{"key":"2022060701170286800_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1158\/2159-8290.CD-15-1283","article-title":"Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov"},{"key":"2022060701170286800_bib15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion\u2013positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2016","journal-title":"Cancer Discov"},{"key":"2022060701170286800_bib16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1158\/2159-8290.CD-15-0399","article-title":"Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor","volume":"5","author":"Piotrowska","year":"2015","journal-title":"Cancer Discov"},{"key":"2022060701170286800_bib17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","article-title":"Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov"},{"key":"2022060701170286800_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrclinonc.2015.175","article-title":"The influence of subclonal resistance mutations on targeted cancer therapy","volume":"13","author":"Schmitt","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2022060701170286800_bib19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nm.3841","article-title":"Studying clonal dynamics in response to cancer therapy using high-complexity barcoding","volume":"21","author":"Bhang","year":"2015","journal-title":"Nat Med"},{"key":"2022060701170286800_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12885-015-1311-0","article-title":"Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy","volume":"15","author":"Heydt","year":"2015","journal-title":"BMC Cancer"},{"key":"2022060701170286800_bib21","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"key":"2022060701170286800_bib22","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s41551-017-0126-5","article-title":"Multiplexed enrichment of rare DNA variants via sequence-selective and temperature-robust amplification","volume":"1","author":"Wu","year":"2017","journal-title":"Nat Biomed Eng"},{"key":"2022060701170286800_bib23","doi-asserted-by":"crossref","first-page":"39595","DOI":"10.18632\/oncotarget.9153","article-title":"Efficacy of the combination of MEK and CDK4\/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"key":"2022060701170286800_bib24","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.288.5473.2045","article-title":"Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6","volume":"288","author":"Volarevic","year":"2000","journal-title":"Science"},{"key":"2022060701170286800_bib25","doi-asserted-by":"crossref","first-page":"e27509","DOI":"10.1371\/journal.pone.0027509","article-title":"S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer","volume":"6","author":"Nawroth","year":"2011","journal-title":"PLoS One"},{"key":"2022060701170286800_bib26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.celrep.2012.02.007","article-title":"PI3K-Akt-mTORC1-S6K1\/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORgamma","volume":"1","author":"Kurebayashi","year":"2012","journal-title":"Cell reports"},{"key":"2022060701170286800_bib27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1042\/BJ20101024","article-title":"Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1)","volume":"431","author":"Pearce Laura","year":"2010","journal-title":"Biochem J"},{"key":"2022060701170286800_bib28","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.neo.2014.08.011","article-title":"Resistance to selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation","volume":"16","author":"Grasso","year":"2014","journal-title":"Neoplasia"},{"key":"2022060701170286800_bib29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2011.38.3224","article-title":"Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer","volume":"30","author":"Su","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022060701170286800_bib30","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1002\/cncr.28711","article-title":"Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations","volume":"120","author":"Lee","year":"2014","journal-title":"Cancer"},{"key":"2022060701170286800_bib31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/annonc\/mdv005","article-title":"Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment","volume":"26","author":"Morelli","year":"2015","journal-title":"Ann Oncol"},{"key":"2022060701170286800_bib32","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-17-0343","article-title":"Tumor evolution as a therapeutic target","author":"Amirouchene-Angelozzi","year":"2017","journal-title":"Cancer Discov"},{"key":"2022060701170286800_bib33","doi-asserted-by":"crossref","first-page":"196ra98","DOI":"10.1126\/scitranslmed.3005753","article-title":"TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma","volume":"5","author":"Corcoran","year":"2013","journal-title":"Sci Transl Med"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/8\/5\/556\/1840248\/556.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/8\/5\/556\/1840248\/556.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T21:17:35Z","timestamp":1654550255000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/8\/5\/556\/9798\/A-Preexisting-Rare-PIK3CAE545K-Subpopulation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,30]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,4,30]]},"published-print":{"date-parts":[[2018,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-17-0745","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.22532392.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532398.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532398","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532395","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532395.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532392","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.6546715.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546715","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,30]]}}}